Clinical Trials | May 07, 2026
GRIN Therapeutics launches Phase 3 beeline study in Europe for radiprodil in GRIN-NDD
This is an exciting and meaningful milestone for GRIN Therapeutics
This is an exciting and meaningful milestone for GRIN Therapeutics
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
The company informed stock exchanges that the appellate authority has set aside the GST demand along with applicable interest and penalty
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
The company has also launched Elyara, a portfolio of products in regenerative medical aesthetics focused on non-invasive skin and hair restoration
The private funding rose 38% amid growing international collaborations and CDMO demand
Company plans to appeal against CGST order related to alleged inadmissible input tax credit claims
Keeps Halo Pharma to drive independent growth
Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology
Subscribe To Our Newsletter & Stay Updated
